News and Announcements
Systemate Collaborates with Northern NSW Waste Management Company
- Published February 10, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Systemate announces partnership to co-develop AI technologies which will automate recycled waste data collection. Northern NSW recycled waste management company Revolve Your World, has partnered with Systemate to utilise the no code data management system and develop custom data applications, to integrate directly within the waste processing facilities.
With a large R&D project on the horizon and currently enjoying significant growth, Revolve Your World is deploying into new regions . The partnership with Systemate enables smart, streamlined efficient data management in this recycled waste growth industry.
About The Company
Systemate is an automated, agile, go anywhere no-code SaaS platform for data management. With features including AI assisted app design, workflow automation, mobile offline mode and API’s to intergrade with 3rd parties or IoT we have an edge in this booming industry. We have built the platform, attracted a stellar team and have a recurring subscription revenue in the APAC market.
Company Updates
The RBA Just Validated the Shift to Private Credit
With the RBA’s latest decision confirming the ‘higher for longer’ environment, sophisticated investors are rotating capital from rate-sensitive public markets into private credit for superior, lower-volatility yields. The era of cheap money is over, making private credit a necessary multi-year positioning decision.
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t
The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.
The Life Sciences Supercycle: Why Australian Biotech is Finally Delivering Billion-Dollar Outcomes
Australia’s life sciences sector is experiencing an unprecedented “Supercycle,” finally commercializing world-class research into global, billion-dollar businesses. Learn about the ASX heavyweights, the key drivers (AI, institutional execution, FDA pathway), and the investment opportunity at Emergence 2026.
Backed By Leading Investment Groups and Family Offices
